EPHA1 and breast cancer: Ideally, clinical trials in large patient collectives need to be conducted, with a view to verifying the clinical utility and safety of the agents targeting members of the EPH/ephrin system in BC, investigating eventual adverse side effects following their administration to patients, as well as determining their efficacy depending on EPH/ephrin expression by BC cells.